11.10
前日終値:
$11.86
開ける:
$12.03
24時間の取引高:
1.84M
Relative Volume:
2.18
時価総額:
$1.43B
収益:
$628.25M
当期純損益:
$-78.55M
株価収益率:
-17.90
EPS:
-0.62
ネットキャッシュフロー:
$-29.73M
1週間 パフォーマンス:
-23.02%
1か月 パフォーマンス:
-21.72%
6か月 パフォーマンス:
-32.44%
1年 パフォーマンス:
-32.65%
Neogenomics Inc Stock (NEO) Company Profile
NEO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NEO
Neogenomics Inc
|
11.10 | 1.43B | 628.25M | -78.55M | -29.73M | -0.62 |
![]()
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
![]()
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
![]()
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
2024-12-10 | 開始されました | Jefferies | Buy |
2024-05-01 | 再開されました | Craig Hallum | Buy |
2023-12-29 | 繰り返されました | BTIG Research | Buy |
2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
2023-02-01 | アップグレード | Needham | Hold → Buy |
2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
2022-08-22 | ダウングレード | Needham | Buy → Hold |
2022-06-03 | 開始されました | Piper Sandler | Overweight |
2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
2022-01-18 | 再開されました | Stephens | Overweight |
2021-12-16 | 開始されました | Cowen | Outperform |
2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
2021-06-03 | 開始されました | Goldman | Buy |
2021-02-25 | 再開されました | Needham | Buy |
2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2021-01-28 | 開始されました | Truist | Buy |
2020-12-11 | 再開されました | BTIG Research | Buy |
2020-10-28 | 繰り返されました | Needham | Buy |
2020-09-09 | 開始されました | Morgan Stanley | Overweight |
2020-08-28 | 開始されました | Guggenheim | Buy |
2020-07-29 | 繰り返されました | Needham | Buy |
2020-06-25 | 開始されました | BofA/Merrill | Buy |
2020-04-21 | 再開されました | Stephens | Overweight |
2020-03-02 | 再開されました | Craig Hallum | Buy |
2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
2019-10-30 | 繰り返されました | Needham | Buy |
2019-05-01 | 繰り返されました | Needham | Buy |
2019-03-29 | 繰り返されました | Needham | Buy |
2019-01-03 | 開始されました | Needham | Buy |
2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
2018-08-21 | 開始されました | Leerink Partners | Outperform |
2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
2017-08-24 | 開始されました | Gabelli & Co | Buy |
2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
NeoGenomics plummets on Q4 2024 bottom line miss, soft EPS guidance - MSN
Bank of America Issues Pessimistic Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
NeoGenomics (NASDAQ:NEO) Price Target Cut to $18.00 by Analysts at Needham & Company LLC - MarketBeat
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021 - ACCESS Newswire
BTIG cuts Neogenomics price target to $17, maintains Buy rating - Investing.com India
BTIG cuts Neogenomics price target to $17, maintains Buy rating By Investing.com - Investing.com Canada
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2024 Earnings Call Transcript - MSN
NeoGenomics (NASDAQ:NEO) Sets New 52-Week Low After Earnings Miss - MarketBeat
Morgan Stanley cuts Neogenomics stock target to $17 from $18 By Investing.com - Investing.com Canada
NeoGenomics (NASDAQ:NEO) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
NeoGenomics price target lowered to $19 from $20 at TD Cowen - TipRanks
NeoGenomics (NASDAQ:NEO) Issues Earnings Results - MarketBeat
NeoGenomics targets 1M patients annually by 2028 with 11%-13% revenue growth in 2025 - MSN
Demystifying NeoGenomics: Insights From 6 Analyst Reviews - Benzinga
NeoGenomics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
NeoGenomics: Q4 Earnings Snapshot - CT Insider
NeoGenomics Inc (NEO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Parp Inhibitor Biomarkers Market Future Business - openPR
NeoGenomics Achieves Double-Digit Revenue Growth in 2024 - TipRanks
Raymond James holds Neogenomics at Market Perform By Investing.com - Investing.com Nigeria
NeoGenomics Q4 Earnings Call Highlights Growth Amid Challenges - TipRanks
NeoGenomics Quarterly Results: Shares Plummet Amidst Financial ConcernsNews and Statistics - IndexBox, Inc.
Why NeoGenomics (NEO) Shares Are Trading Lower Today By Stock Story - Investing.com Canada
Why NeoGenomics (NEO) Shares Are Trading Lower Today - Financial Content
NeoGenomics stock tumbles on weak EPS guidance By Investing.com - Investing.com Nigeria
Trend Tracker for (NEO) - Stock Traders Daily
NeoGenomics (NEO) Tops Q4 Earnings Estimates - MSN
Earnings call transcript: NeoGenomics Q4 2024 earnings beat expectations, stock drops - Investing.com
NeoGenomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Raymond James holds Neogenomics at Market Perform - Investing.com India
Neogenomics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt - Simply Wall St
NeoGenomics reports Q4 adjusted EPS 4c, consensus 3c - TipRanks
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results - BioSpace
NEOGENOMICS Earnings Results: $NEO Reports Quarterly Earnings - Nasdaq
Earnings Flash (NEO) NeoGenomics Posts Q4 Revenue $172M, vs. FactSet Est of $173.2M - Marketscreener.com
Neogenomics Inc Reaffirms Full-Year 2025 Guidance -February 18, 2025 at 07:19 am EST - Marketscreener.com
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets - Yahoo Finance
Not Just a DEX: How Pineapple’s Mystery Marketing is Changing the Game - GlobeNewswire Inc.
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect - MSN
NeoGenomics Set to Surpass Revenue Growth ProjectionsNews and Statistics - IndexBox, Inc.
Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Target Price at $20.20 - MarketBeat
NeoGenomics (NEO) Projected to Post Earnings on Tuesday - MarketBeat
NeoGenomics Q4 2024 Earnings Preview - MSN
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter - ACCESS Newswire
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021 - ACCESS Newswire
NeoGenomics Enters Strategic Collaboration with Inivata to Commercialize InVisionFirst(R)-Lung Liquid Biopsy Test - ACCESS Newswire
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors - ACCESS Newswire
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):